Generic name: aripiprazole
Brand name: Abilify
Class: Atypical antipsychotic
FDA Indications: schizophrenia, bipolar disorder. Non-FDA listed indications include depression and autism.
Pharmacology/pharmacokinetics: Partial dopamine and serotonin agonist and 5-HT2A antagonist. Half life is up to 94 hours, due in part to its high binding affinity to albumin.
Interactions: CYP3A4 inducers (such as carbamazepine) may decrease plasma levels, CYP3A4 inhibitors (such as fluoxetine and paroxetine) may increase plasma levels.
Contraindications: Not recommended for patients with dementia-related psychosis. Use with caution in patients with cardiovascular conditions and in patients with seizure disorders.
Adverse effects: headaches, anxiety, insomnia, nausea, vomiting, lightheadedness, tardive dyskinesia.
Patient consultation: Use caution with preforming tasks that require mental alertness (IE: driving), avoid alcohol, stay hydrated.
Other facts: Research in animal models has shown that it may block cocaine-seeking behavior without interfering with other rewarding behaviors. Other studies have shown that it may increase the stimulant and euphoric effects of methamphetamine and may also increase the baseline desire for methamphetamine.